Inmune Bio (INMB) Equity Average (2018 - 2025)
Inmune Bio (INMB) has disclosed Equity Average for 8 consecutive years, with $24.5 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 30.9% to $24.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.5 million through Dec 2025, down 30.9% year-over-year, with the annual reading at $27.8 million for FY2025, 19.9% down from the prior year.
- Equity Average hit $24.5 million in Q4 2025 for Inmune Bio, down from $27.1 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $84.2 million in Q4 2021 to a low of $24.5 million in Q4 2025.
- Historically, Equity Average has averaged $49.1 million across 5 years, with a median of $49.2 million in 2021.
- Biggest five-year swings in Equity Average: soared 142.21% in 2021 and later tumbled 43.19% in 2024.
- Year by year, Equity Average stood at $84.2 million in 2021, then fell by 26.51% to $61.9 million in 2022, then tumbled by 34.36% to $40.6 million in 2023, then dropped by 12.92% to $35.4 million in 2024, then tumbled by 30.9% to $24.5 million in 2025.
- Business Quant data shows Equity Average for INMB at $24.5 million in Q4 2025, $27.1 million in Q3 2025, and $29.3 million in Q2 2025.